CN-122005628-A - Lactobacillus rhamnosus fermentation metagen, preparation method thereof and application thereof in improving atherosclerosis, reducing thrombosis risk and regulating ceramide metabolism

Abstract

The invention belongs to the technical field of preparation of post-fermentation prebiotics, and particularly relates to a post-fermentation prebiotic of lactobacillus rhamnosus, a preparation method thereof and application thereof in improving atherosclerosis, reducing thrombosis risk and regulating ceramide metabolism. In the preparation process of the lactobacillus fermentation metagen, the yeast protein releases the polypeptide with vasodilation and inflammation inhibition functions, and after compatibility with anthocyanin and arabinoxylan oligosaccharide with functions of regulating ceramide metabolism and protecting cardiovascular, the lactobacillus fermentation metagen with functions of protecting cardiovascular and cerebrovascular is formed under the fermentation action of lactobacillus rhamnosus NKU ML1-2, and the lactobacillus fermentation metagen can directly act on vascular cells through multiple ways as a dietary nutrition intervention means to promote endothelial cell function repair, inhibit endothelial cell apoptosis and oxidative damage and regulate ceramide substance generation, thereby providing an innovative nutrition intervention strategy for preventing and treating atherosclerosis related diseases and preventing thrombosis.

Inventors

• LIU JIANBIN
• FU WENHUI
• WANG XIAODAN

Assignees

• 天赋能健康产业集团股份有限公司
• 南开大学

Dates

Publication Date

20260512

Application Date

20260415

Claims (10)

1. 1. A preparation method of a lactobacillus fermented metaplasia is characterized by comprising the following steps of inoculating lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) NKU ML1-2 into a fermentation system for liquid fermentation to obtain a liquid fermentation product, wherein the biological preservation name of the lactobacillus rhamnosus NKU ML1-2 is Lacticaseibacillus rhamnosus NKU ML-2, the taxonomic name is Lacticaseibacillus rhamnosus, the preservation date is 2025, 8 and 13 days, the preservation unit is named Guangdong province microorganism strain preservation center, the preservation unit is GDMCC, the preservation address is Guangzhou city martyr, the No. 100 university building 5 is building, and the preservation number is GDMCC No: 66837; removing thalli in the liquid fermentation product to obtain the lactobacillus post-fermentation metaplasia; The fermentation system takes water as a solvent and comprises yeast protein, arabinoxylan and blueberry powder, wherein the addition amount of the yeast protein is 10% -15% of the mass of the fermentation system, the addition amount of the arabinoxylan is 2% -10% of the mass of the fermentation system, the addition amount of the blueberry powder is 0.2% -1% of the mass of the fermentation system, and the anthocyanin content in the blueberry powder is 20% -40%.
2. 2. The preparation method according to claim 1, wherein the lactobacillus rhamnosus NKU ML1-2 is inoculated in an amount of 10 7 ~10 9 CFU/ML.
3. 3. The preparation method of claim 1, wherein the liquid fermentation is a shaking fermentation, the rotation speed of the shaking fermentation is 180-220 rpm, the temperature of the shaking fermentation is 35-40 ℃, and the time of the shaking fermentation is 22-26 h.
4. 4. A post-fermentation prebiotic of Lactobacillus is characterized in that the post-fermentation prebiotic of Lactobacillus is prepared by the preparation method of any one of claims 1-3, and contains short chain fatty acids and/or polypeptides.
5. 5. The lactobacillus fermentum metazoan according to claim 4, wherein the short chain fatty acids comprise one or more of butyric acid, propionic acid, acetic acid, pelargonic acid, caproic acid, heptanoic acid, isobutyric acid, isovaleric acid, valeric acid, capric acid and caprylic acid.
6. 6. Use of one or both of the following post-fermentation primordia of lactobacillus as claimed in claim 4 or claim 5: 1) Use in the preparation of a product for preventing and/or ameliorating atherosclerosis; 2) Use in the preparation of a product for preventing thrombosis.
7. 7. The use according to claim 6, wherein the product comprises a product for improving vascular endothelial dysfunction.
8. 8. The use of claim 7, wherein the improvement of vascular endothelial dysfunction comprises one or more of improvement of vascular cell inflammatory injury, improvement of vascular cell oxidative damage, and modulation of vascular cell ceramide metabolism.
9. 9. A product for preventing and/or ameliorating atherosclerosis, characterized in that the product comprises the lactobacillus post-fermentation metaplasia of claim 4 or 5.
10. 10. The product according to claim 9, wherein the lactobacillus post-fermentation metazoan is the only active ingredient.

Description

Lactobacillus rhamnosus fermentation metagen, preparation method thereof and application thereof in improving atherosclerosis, reducing thrombosis risk and regulating ceramide metabolism Technical Field The invention belongs to the technical field of preparation of post-fermentation prebiotics, and particularly relates to a post-fermentation prebiotic of lactobacillus rhamnosus, a preparation method thereof and application thereof in improving atherosclerosis, reducing thrombosis risk and regulating ceramide metabolism. Background Atherosclerosis (AS) is a chronic inflammation of the wall of blood vessels, and ceramides and tumor necrosis factor-alpha (TNF-alpha) can enhance vascular inflammation to affect the development of Atherosclerosis. Meanwhile, AS is also a main pathogenesis of coronary heart disease, and has become one of important causes of death of non-infectious diseases. In some studies known to the inventors, vascular endothelial dysfunction is a central link in the development and progression of AS, and endothelial cell (EPCs) activity and oxidative stress levels are closely related to AS progression. In addition, ceramide substances show remarkable aggregation in AS development, promote necrotic core formation by inducing macrophage apoptosis, and exacerbate plaque instability. Currently, the existing medicines for treating atherosclerosis mainly comprise statin lipid-lowering medicines, antiplatelet medicines, antihypertensive medicines and the like. However, statins may cause adverse reactions such as muscle pain, liver injury, blood glucose elevation, etc., antiplatelet drugs such as aspirin increase the risk of bleeding, and prolonged administration may bring about cumulative toxicity. Compared with some existing probiotics and the composition products thereof known by the inventor, the stability of the metazoan work is high, the metazoan work is not influenced by biological activity, the safety is higher, and the metazoan work is particularly characterized in that 1) the stability is obviously better than that of the existing probiotics and the compositions thereof, wherein the existing probiotics and the compositions thereof depend on activity of living bacteria, the living bacteria are sensitive to temperature, acid and alkali, processing, storage and other environments, the survival rate is easy to be reduced, the activity is maintained by a cold chain and special embedding, and the production, storage and transportation cost and difficulty are increased. The metazoan is an inanimate microorganism and active ingredient compound, does not need to rely on living bacteria, has extremely strong environmental tolerance, has stable efficacy components under normal-temperature storage and high-temperature processing, does not need special protection, is suitable for various products, reduces storage and transportation cost, and is convenient for large-scale popularization. 2) The effect is stable and controllable without being influenced by biological activity, the effect of the existing probiotics depends on the intestinal field planting of living bacteria, the effect is greatly influenced by the individual differences of environment and hosts, and the unstable effect and even ineffective effect can be caused by insufficient living bacteria or field planting failure. The metazoan does not contain viable bacteria, the functional components can be directly absorbed by human bodies, the effects are not influenced by individual differences and the activity of the viable bacteria, the effects are stable and controllable, the precise regulation and control of the component content can be realized, and the effects of the metazoan are not inferior to those of the viable bacteria probiotics after the verification of part. 3) The safety is higher than that of the existing probiotics and the composition thereof, the existing probiotics contain living bacteria, the infection risk and the flora shift risk are caused for special people with low immunity and the like, part of strains possibly carry drug resistance genes, and the strain can fail and increase the hidden health trouble when being used together with antibiotics. 4) The metazoan is inactivated, sterilized, stopped from related safety risks, adapted to special groups, clear in components, purified, free from drug resistance gene risks, applicable to antibiotics, wide in applicable groups, free from obvious adverse reaction in clinic, and outstanding in safety advantages. It can be seen that the advantages of the metagen in terms of stability, bioactivity and safety are obvious compared with those of the probiotics and the composition products thereof, but the metagen products with the effect of improving atherosclerosis-related symptoms are still required to be further developed and researched. Disclosure of Invention The invention aims to provide lactobacillus rhamnosus fermentation metagen, a preparation method thereof and application thereo